Effect of high sensitivity C-Reactive Protein on Uric Acid-related Cardiometabolic Risk in Patients with Coronary Artery Disease

Ying Song,Weiting Cai,Lin Jiang,Jingjing Xu,Yi Yao,Na Xu,Xiaozeng Wang,Zhenyu Liu,Zheng Zhang,Yongzhen Zhang,Xiaogang Guo,Zhifang Wang,Ying-qing Feng,Qingsheng Wang,Jianxin Li,Xueyan Zhao,Jue Chen,Runlin Gao,Lei Song,Yaling Han,Jinqing Yuan
DOI: https://doi.org/10.1101/2024.06.21.24309325
2024-06-24
Abstract:Aims Although serum uric acid (SUA) is a risk factor for cardiometabolic outcome, but it remains unclear which patients with coronary artery disease (CAD) benefit the most from SUA lowering therapy (ULT). The association of SUA level, systemic inflammation and cardiometabolic risk is still unclear. The current study is aimed to examine whether SUA-associated cardiometabolic risk is modulated by systemic inflammation in CAD patients. Methods and Results A total of 16,598 CAD patients with baseline high-sensitivity C-Reactive Protein (hsCRP) and SUA available were included. Baseline and follow-up data were collected. The primary endpoint was major adverse cardiovascular and cerebrovascular events (MACCE), including death, myocardial infarction and stroke. In patients with hsCRP ?2 mg/L, increasing quintiles of SUA were significantly associated with increased rates of 2-year MACCE (adjusted p < 0.001 for trend, p = 0.037 for interaction). Each unit increase in SUA levels was associated with a 11.3% increased risk of MACCE (adjusted p < 0.001, p = 0.002 for interaction). However, in patients with hsCRP < 2mg/L, increasing quintiles of SUA were not associated with increased MACCE (adjusted p = 0.120). Conclusion Elevated SUA levels are related to MACCE when hsCRP levels are 2 mg/L or more but not less than 2mg/L. This finding suggests a potential benefit of combined ULT and anti-inflammation therapy in patients with hyperuricemia and greater systemic inflammation.
What problem does this paper attempt to address?
The problem that this paper attempts to solve is to explore the impact of high - sensitivity C - reactive protein (hsCRP) levels on serum uric acid (SUA) - related metabolic cardiovascular risks in patients with coronary artery disease (CAD). Specifically, the study aims to evaluate how the relationship between SUA levels and systemic inflammation affects the risk of major adverse cardiovascular and cerebrovascular events (MACCE) in CAD patients. By analyzing a large amount of multi - center prospective cohort data, researchers hope to clarify whether SUA levels are associated with a higher risk of MACCE in CAD patients with higher levels of systemic inflammation, and how this association is manifested in different subgroups. The research background indicates that although SUA is considered a risk factor for cardiometabolic outcomes, it is still unclear which CAD patients would benefit the most from SUA - lowering treatments. In addition, the relationship between SUA levels, systemic inflammation, and cardiometabolic risks remains unclear. Therefore, the main purpose of this study is to explore whether SUA - related metabolic cardiovascular risks are modulated by systemic inflammation in CAD patients.